Appendix B: Panel Roster and Financial Disclosures
Human Papillomavirus
| Member | Institution | Financial Disclosure | |
|---|---|---|---|
| Company | Relationship | ||
| Darron Brown | Indiana University School of Medicine | Pfizer Johnson & Johnson Novavax Lilly |
Equity Interest |
| PDS Biotechnologies | Scientific Advisory Board | ||
| Merck | Research Support (paid to institution) | ||
| Susan Cu-Uvin* | Brown University, Warren Alpert Medical School | United Nations Population Fund | Research Support (paid to institution) |
| Mark Einstein | Rutgers New Jersey Medical School |
AstraZeneca Iovance |
Research Support (paid to institution) |
|
Becton-Dickinson, and Company Inovio PDS Biotechnologies |
Consulting Fee (paid to institution) | ||
| Lauri Markowitz | Centers for Disease Control and Prevention | None | N/A |
| L. Stewart Massad | Washington University School of Medicine in St. Louis | None | N/A |
| Anna-Barbara Moscicki | David Geffen School of Medicine at the University of California, Los Angeles | Merck | Scientific Advisory Board |
| Joel Palefsky | University of California, San Francisco School of Medicine | Merck | Research Support (paid to institution) |
| Elizabeth Stier | Boston University Medical Center | None | N/A |
| Howard Strickler | Albert Einstein College of Medicine | Arbor Vista MTM Laboratories/Ventura-Roche BD Diagnostics |
Research Support (paid to institution) |
| John Weiser | Centers for Disease Control and Prevention | None | N/A |
| Timothy Wilkin | New York - Presbyterian/Weill Cornell Medicine | Merck | Scientific Advisory Board |
| Merck ViiV Healthcare |
Research Support (paid to institution) | ||
| * Section Group Lead Note: Members are required to update disclosures annually and to notify guideline staff of any relevant changes in status during the interim. |
|||
Download Guidelines
- Section Only PDF (44.68 KB)
- Full Guideline PDF (6 MB)
- Tables Only PDF (928.12 KB)